Abstract

AZELNIDIPINE: A REVIEW ON THERAPEUTIC ROLE IN HYPERTENSION

Girindra Lekhi* and Chandanam Sreedhar

ABSTRACT

The elevated risk linked with high blood pressure (BP) can be considerably decreased by treatment with antihypertensive medications that lower both BP and related causes of organ damage. New Ca2+ channel antagonists have recently been discovered, particularly DHP compounds, which have significantly higher vascular selectivity, a slower onset, and a longer duration of hypotensive activity. Azelnidipine's antihypertensive impact is primarily due to its blockage of trans-membrane Ca2+ influx through vascular smooth muscle voltage-dependent channels. Ca2+ channels are categorized into several subtypes, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels depend on their electrophysiological properties. Electrophysiological features of Ca2+ channels are important. Azelnidipine has been shown in clinical tests to reduce heart rate and proteinuria in hypertension individuals by reducing sympathetic nerve activity. Azelnidipine has also been discovered to prevent insulin resistance and possesses cardioprotective, neuroprotective, and anti-atherosclerotic characteristics.

Keywords: calcium channel blocker, hypertension, Azelnidipine, Dihydropyridine, Blood pressure.